The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival

Hellou, Tamer; Cohen, Ornit; Avigdor, Abraham; Amitai, Irina; Shimoni, Avichai; Misgav, Mudi; Canaani, Jonathan

doi:10.1007/s00277-023-05158-w

Cited by 5 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our univariate analyses of disease-related parameters identified an adverse genetic risk score as being predictive of ATE. Martella et al's and Hellou et al's studies, which explored the risk factor for VTE in AML patients, described patients with intermediate-risk cytogenetics as having an increased risk for venous thrombosis [14,23]. In contrast, Lee YG's study showed that advanced cytogenetic risk was an independent predictor for VTE development [16].…”

Section: Discussionmentioning

confidence: 99%

Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors

Mitrović

Pantić

Sabljić

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Patients with hematological malignancies have an increased risk of arterial thrombotic events (ATEs) after diagnosis, compared to matched controls without cancer. However, data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Aim: The objectives of this study were to determine the incidence of ATE in non-promyelocytic-AML patients and to define the potential risk factors for ATE development. Methods: We conducted a retrospective cohort study of adult patients with newly diagnosed AML. The primary outcome was the occurrence of confirmed ATE, defined as myocardial infarction, stroke or critical limb ischemia. Results: Out of 626 eligible AML patients, 18 (2.9%) patients developed ATE in the median time of 3 (range: 0.23–6) months. Half of these patients died due to ATE complications. Five parameters were predictors of ATE: BMI > 30 (p = 0.000, odds ratio [OR] 20.488, 95% CI: 6.581–63.780), prior history of TE (p = 0.041, OR 4.233, 95% CI: 1.329–13.486), presence of comorbidities (p = 0.027, OR 5.318, 95% CI: 1.212–23.342), presence of cardiovascular comorbidities (p < 0.0001, OR 8.0168, 95% CI: 2.948–21.800) and cytogenetic risk score (p = 0.002, OR 2.113, 95% CI: 1.092–5.007). Conclusions: Our study showed that patients with AML are at increased risk of ATE. The risk was increased in patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30.

show abstract

Section: Discussionmentioning

confidence: 99%

Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors

Mitrović

Pantić

Sabljić

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…26 However, novel data regarding the impact of thromboembolism on survival in AML patients stressed that VTE did not influence ED or overall survival rate. [27][28][29] Conversely, authors showed that arterial thromboses led to increased risk of early mortality and were associated with poorer overall survival. 30,31 Results of thromboembolic impact on mortality in the setting of APL are scarce.…”

Section: Impact Of Thrombosis On Early Death and Overall Survivalmentioning

confidence: 99%

Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding

Sabljic,

Mitrovic,

Pantic

et al. 2024

Hamostaseologie

View full text Add to dashboard Cite

Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores. Besides, prophylactic use of anticoagulants and recombinant thrombomodulin are a matter of ongoing debate. Also, due to the common feature of thrombocytopenia and other hemorrhagic risks, patients with APL are excluded from trials analyzing anticoagulant prophylaxis in cancers; so, data from prospective trials are lacking. A detailed analysis of thrombotic risks in APL with the development of a reliable risk stratification model is needed to further improve the care of APL patients.

show abstract

Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges

Olivi

Biase

Lanzarone

et al. 2023

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival

Cited by 5 publications

References 22 publications

Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors

Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors

Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding

Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges

Contact Info

Product

Resources

About